Evaluation of Thoraflex in the Treatment of Aneurysm or Penetrating Ulcer of the Descending Thoracic Aorta

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01357590
Recruitment Status : Withdrawn
First Posted : May 20, 2011
Last Update Posted : March 2, 2012
Information provided by (Responsible Party):
Vascutek Ltd.

Brief Summary:

ThoraflexTM is designed for the treatment of aneurysm or penetrating ulcer of the descending thoracic aorta. Each system is advanced from a transfemoral or transiliac approach over a 0.035" guidewire and positioned under fluoroscopic control. If necessary, an arterial conduit technique may be required to allow access to the arterial system. The soft tapered tip allows atraumatic insertion into the vessel, while the catheter and sheath are designed to provide excellent flexibility and control through tortuous arterial anatomy.

Each individual stent graft device is supplied sterile and pre-loaded in a single-use delivery system. The stent graft is a self-expanding endoprosthesis constructed of a thin wall woven polyester and nitinol ring stents, which are attached to the fabric with braided polyester sutures. The delivery system central catheter is a stainless steel braided co-extrusion of polytetrafluoroethylene (PTFE) and polyester elastomer, designed to provide significant torque control and strength, while also maintaining superior flexibility. The outer sheath is made in a tri-layer construction consisting of a PTFE liner, a stainless steel flat braid layer and a polyester elastomer outer jacket with a hydrophilic lubricant coating. These materials provide very low friction force during device insertion and deployment together with enhanced flexibility of the delivery system. The handle components are moulded from thermoplastic polyurethane.

The materials of the endoprosthesis are identical to those of the current Conformité Européenne (CE) marked Vascutek Ltd. AnacondaTM Stent Graft System intended for abdominal aortic aneurysm repair. The materials of the delivery system are well established in medical applications. The design of ThoraflexTM is based on the same principles as other clinically established thoracic endovascular devices. The endoprosthesis is constructed of self-expanding nitinol stents and a polyester tube graft. Four proximal hooks anchor the endoprosthesis within the aorta. Unlike existing thoracic endovascular devices, the delivery system of ThoraflexTM allows repositioning of the endoprosthesis so that the optimal deployment position can be enhanced.

The intended use of ThoraflexTM is the treatment of aneurysm or penetrating ulcer of the descending thoracic aorta, which is identical to other CE approved thoracic endovascular devices.

Condition or disease Intervention/treatment Phase
Aortic Aneurysm, Thoracic Penetrating Aortic Ulcers (PAUs) Device: Thoracic Endovascular Stent Graft System (ThoraflexTM) Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Evaluation of the Vascutek Ltd. Thoracic Endovascular Stent Graft System (ThoraflexTM)in the Treatment of Aneurysm or Penetrating Ulcer of the Descending Thoracic Aorta

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Aneurysms

Intervention Details:
  • Device: Thoracic Endovascular Stent Graft System (ThoraflexTM)
    Thoracic Endovascular Stent Graft System

Primary Outcome Measures :
  1. Successful aneurysm/PAU treatment, defined as a composite endpoint of Subjects who have successful delivery and deployment of the ThoraflexTM at the initial procedure and are free from the following; [ Time Frame: (less than or equal to) 365 days post-procedure ]
    1. Aneurysm growth (greater than or equal to) 5mm from baseline measurement
    2. Post-operative interventions to correct type I or III endoleaks
    3. Conversion to open surgical repair
    4. Failed patency of the stent graft
    5. Migration requiring secondary intervention
    6. Significant failure of stent graft integrity
    7. Aneurysm rupture

Secondary Outcome Measures :
  1. Incidence of type I or III endoleak. The incidence of Subjects with freedom from type I and III endoleaks will be the focus of assessments; however type II and IV endoleaks will be recorded and evaluated for rates of occurrence [ Time Frame: First 24 hour post-operative period (defined on procedural angiography) ]
  2. Stent graft patency, described as the presence of blood flow within the graft as determined through imaging analysis [ Time Frame: First 24 hour post-operative period (defined on procedural angiography) ]
  3. Conversion to surgical repair [ Time Frame: First 24 hour post-operative period (defined on procedural angiography) ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Subject aged > 18 years
  2. Subject has a life expectancy of at least 12 months
  3. The Subject must meet at least one of the following:

    1. Descending thoracic fusiform aneurysm, 50mm in diameter or greater. ONLY FOR FRENCH SITES: Descending thoracic fusiform aneurysm, 5.5cm in diameter or greater.
    2. Descending thoracic aneurysm that is 4cm or more in diameter that has increased in size by 0.5cm in last 6 months. ONLY FOR FRENCH SITES: Descending thoracic aneurysm that is 4cm or more in diameter that has increased in size by 1cm in the last year
    3. Descending thoracic aneurysm with a maximum diameter that exceeds two times the diameter of the non-aneurysmal, adjacent aorta
    4. Saccular aneurysm in the descending thoracic aorta or Penetrating Atherosclerotic Ulcers (PAUs). ONLY FOR FRENCH SITES: Saccular aneurysm in the descending thoracic aorta, Penetrating Atherosclerotic Ulcers (PAUs) with associated Intramural Haematoma, or Atherosclerotic Giant PAU
  4. Subject must have proximal and distal aortic neck suitable for stent graft placement with vessel diameter ranging between 22.0 - 35.0 mm.
  5. The length of attachment zones will depend on the intended stent graft diameter. For left subclavian artery (LSA) in superior position: The proximal attachment zone should be 10mm for 28mm graft, 11mm for 30mm, 12mm for 32mm - 34mm grafts, 14mm for 36mm - 38mm grafts and 15mm for 40mm graft. For LSA in non-superior position: The proximal attachment zone should be 15mm for 28mm graft, 17mm for 30mm, 20mm for 32mm - 34mm grafts, 23mm for 36mm - 38mm grafts and 25mm for 40mm graft. The distal attachment zone should be 40mm.
  6. The diagnosis is confirmed as thoracic aortic aneurysm or PAU by contrast enhanced CT obtained within the three months prior to implant.
  7. Access vessels: Adequate iliac/femoral access -able to accommodate 23 (7.7 mm) or 25 OD French size (8.3 mm) introducer systems, with or without the use of an arterial conduit.
  8. Subject is able and willing to comply with the protocol and associated follow-up requirements
  9. Subject or legal representative must have agreed to participate voluntarily and have signed and dated an Ethics Committee/Ethical Review Board approved Patient Informed Consent form.

Exclusion Criteria:

  1. Subject has any of the following conditions in his/her descending thoracic aorta:

    1. Dissections - acute or chronic, in ascending or descending aorta
    2. Acute Transection or Acute Traumatic Injury
    3. Pseudoaneurysm (false aneurysm)
    4. Symptomatic Aneurysm, including ruptured lesions
  2. Subject's proximal neck diameter measures < 22.0 or > 35.0 mm.
  3. Subject's distal neck diameter measures < 22.0 or > 35.0 mm.
  4. Subject has prohibitive calcification (>50% circumferential calcification), occlusive disease, or tortuosity of intended fixation sites.
  5. Subject has circumferential thrombus (>50%) in region of intended fixation sites.
  6. Subject has an increasing tapered proximal neck with ≥3mm increase in diameter from proximal fixation site to the aneurysm.
  7. Subject has a decreasing tapered distal neck with ≥3 mm increase in diameter from distal fixation site to the aneurysm.
  8. Subject's aneurysm or distal thoracic aortic neck angle precludes advancement of the introduction system and device.
  9. Subject has an anatomical variance which would compromise circulation to the carotids, vertebral, or innominate arteries after device placement that is not amenable to subclavian revascularisation. This would not apply to Subjects with occluded celiac arteries.
  10. Subject is pregnant.
  11. Subject is morbidly obese preventing adequate x-ray visualization of the aorta.
  12. Subject has known or suspected connective tissue disorder (e.g., Marfan's syndrome, Ehlers-Danlos syndrome).
  13. Subject has a blood coagulation disorder or bleeding diathesis in which the treatment cannot be suspended for one week pre and post repair.
  14. Subject has coronary artery disease with unstable angina and who has not received coronary revascularisation within the last 3 months.
  15. Subject has chronic obstructive pulmonary disease requiring the routine need for oxygen therapy outside the hospital setting (e.g., daily or nightly home use).
  16. Subject is in acute renal failure or renal insufficiency with a creatinine ≥ 2.5 mg/dL and is not on renal replacement therapy or dialysis.
  17. Subject has active systemic infection and/or mycotic aneurysms.
  18. Subject has had a stroke within 3 months of the treatment date.
  19. Subject has less than one-year life expectancy as evidenced by factors prohibiting major medical intervention (e.g., presence of malignant tumour, advanced age, etc.).
  20. Subject is participating in another research study.
  21. Subject has a co-existing abdominal aortic aneurysm (AAA) in which the investigator believes requires concomitant treatment within 45 days.
  22. Subject has had a prior AAA repair (endovascular or surgical) that was performed less than 6 months prior to enrolment.
  23. Subject has had a prior endovascular repair (e.g., stent, stent-graft) in the descending thoracic aorta. The device may not be placed within any prior surgical graft.
  24. Subject has an untreatable allergy or sensitivity to contrast media or device components.
  25. Subject has been admitted to the hospital for a major surgical or medical procedure within45 days of the planned procedure or is planning to undergo other major surgical or medical procedure within 45 days post implantation (e.g., coronary artery bypass graft [CABG], organ transplantation, etc.). This excludes any planned procedures for the prospective stent-graft placement (e.g. common carotid to left subclavian transposition/bypass, left carotid to axillary bypass, etc. are acceptable. Carotid-carotid bypasses are not permitted).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01357590

Cliniques Universitaires Saint-Luc (UCL)
Brussels, Belgium, B-1200
UZ Gent
Gent, Belgium, B-9000
UZ (Universitair Ziekenhuis) Leuven
Leuven, Belgium, 3000 Leuven
Peter Lougheed Centre
Calgary, Canada, AB T1Y 6J4
Institute University de Cardiologie et de
Quebec, Canada, G1V 4G5
Sunnybrook Health Sciences Centre
Toronto, Canada, M4N 3M5
St Michael's Hospital
Toronto, Canada, ON M5B 1W
Service de Chirurgie Cardaque et Vasculaire
Bordeaux, France, 33 604
Hopital Europeen Georges Pompidou
Paris, France, 75908
Service de Radiologie
Toulouse, France, 31403
RWTH Aachen, University Hospital Aachen
Aachen, Germany, 52074
Universitatsklinikum Freiburg
Freiburg, Germany, 79106
Department of Vascular Medicine
Hamburg, Germany, 20246
MH Hannover
Hannover, Germany, 30625
Harzzentru der Universitatsklinik Koln
Koln, Germany, 50924
Klinikum rechts der Isar
Munich, Germany, 81675
Universita di Bologna
Bologna, Italy, 41038
University of Florence
Florence, Italy, 50134
Dipartimento Cardioscienze
Rome, Italy, 00152
VUmc, Department of Surgery
Amsterdam, Netherlands, 1081 HV
Academic Medical Centre (AMC), Department of Surgery
Amsterdam, Netherlands, 1105 AZ
Medisch Specturm Twente, Department of Surgery
Enschede, Netherlands, 7513 ER
University of Maastricht, Department of Surgery
Maastricht, Netherlands, 6229 HX
Erasmus Medical Centre, Department of Surgery
Rotterdam, Netherlands, 3015 CE
United Kingdom
Leeds General Infirmary
Leeds, England, United Kingdom, LS1 3EX
Royal Infirmary of Edinburgh
Edinburgh, Scotland, United Kingdom, ED16 4SA
Western Infirmary
Glasgow, United Kingdom, G11 6NT
St Thomas' Hospital
London, United Kingdom, SE1 7EH
Sponsors and Collaborators
Vascutek Ltd.

Responsible Party: Vascutek Ltd. Identifier: NCT01357590     History of Changes
Other Study ID Numbers: TAA-001
First Posted: May 20, 2011    Key Record Dates
Last Update Posted: March 2, 2012
Last Verified: March 2012

Keywords provided by Vascutek Ltd.:
aneurysm, penetrating ulcer, descending thoracic aorta

Additional relevant MeSH terms:
Aortic Aneurysm
Aortic Aneurysm, Thoracic
Pathologic Processes
Vascular Diseases
Cardiovascular Diseases
Aortic Diseases